Full Press Release Details
Prima BioMed Limited ASX Price Query
I refer to your letter dated 7 January 2016 in relation to the ASX Price Query. Prima BioMed Limited (Prima BioMed) provides the
following responses to the questions in your letter.
1. Question: Is the Entity aware of any information concerning it that has not been released
to the market which, if known by some in the market, could explain the recent trading in its securities?
Response: No; Prima BioMed is not aware of
any such information.
2. Question: If the answer is yes ?
Response: Not applicable.
answer is no , is there any other explanation that the Entity may have for the recent trading in its securities?
Response: Prima BioMed
is aware that it has recently been the subject of favourable research reports from both Roth Capital Partners and Edison. Both reports are available on Prima BioMed s website.
4. Question: Please confirm that the Entity is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
Response: Prima BioMed is compliant with the Listing Rules including Listing Rule 3.1.
If you have any further questions, please do not hesitate to contact me.
Counsel & Company Secretary
Prima BioMed Ltd, Level
12, 95 Pitt Street, Sydney NSW 2000
Phone: +61 2 8315 7003 Fax: +61 2 8569 1880
www.primabiomed.com.au ABN: 90 009 237 889
By email: deanne.miller@primabiomed.com.au
Prima Biomed Ltd (the Entity ):
We have noted a change in the price of the Entity s securities from a close of $0.052 on Wednesday, 6 January 2016 to a high
of $0.059 today, Thursday, 7 January 2016.
We also note an increase in the trading volume of the Entity s securities.
In light of the price and volume increase, ASX asks you to respond separately to each of the following questions:
Please note that the recent trading in the Entity s securities would suggest to ASX that such information may have ceased to be
confidential and therefore the Entity may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is yes , you need to contact us immediately to discuss the situation.
Please note, if the answer to this question is
no , you need to contact us immediately to discuss requesting a trading halt (see below).
When and where to send your response
is made under, and in accordance with, Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by not later than half an hour before the start of trading (ie before 9.30 a.m. AEDT) on Friday 8 January
2016. If we do not have your response by then, ASX will have no choice but to consider suspending trading in the Entity s securities under Listing Rule 17.3.
You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within
the exceptions mentioned in Listing Rule 3.1A, the Entity s obligation is to disclose the information immediately . This may require the information to be disclosed before the deadline set out in the previous paragraph.
ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your
response should be in a form suitable for release to the market.
Your response should be sent to me by e-mail. It should not be sent directly to
the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.
Listing Rule 3.1 requires a listed
entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity s securities. Exceptions to this requirement are set out in Listing Rule 3.1A.
The obligation of the Entity to disclose information under Listing Rules 3.1 and 3.1A is not confined to, nor is it necessarily satisfied by, answering the
questions set out in this letter.
In responding to this letter, you should have regard to the Entity s obligations under Listing Rules 3.1 and 3.1A
and also to Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 3.1B.
If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is yes and an announcement cannot be made
immediately, you should discuss with us whether it is appropriate to request a trading halt in the Entity s securities under Listing Rule 17.1.
you wish a trading halt, you must tell us:
require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.
You can find further information about trading halts in Guidance Note 16 Trading Halts & Voluntary Suspensions.
If you have any queries or concerns about any of the above, please contact me immediately.
[Sent electronically without signature]
Senior Adviser, Listings Compliance